Unfortunately, Grail had bad news for investors in February when it released top-line results from the NHS and outlined that ...

The FDA could approve the first blood test that can detect multiple cancers, around the end of the year, setting the stage ...

CANTON, Mass. & MENLO PARK, Calif.-- (BUSINESS WIRE)--Point32Health, the parent company of Harvard Pilgrim Health Care, and GRAIL, LLC, a health care company with a mission of detecting cancer early ...

Dec 17 (Reuters) - Gene sequencing company Illumina ILMN.O said on Sunday it will divest cancer diagnostic test maker Grail GRAL.O after the companies battled both U ...

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare company whose mission is to detect cancer early when it can be cured, today announced its spin-off ...

MENLO PARK, Calif., & TAMPA, Fla.--(BUSINESS WIRE)-- GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and BeniComp, a customized health plan provider, ...

Add Yahoo as a preferred source to see more of our stories on Google. Multi-cancer blood tests are generally seen as the future of cancer detection. The promise is that with a few vials of blood, you ...

Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for more than two years and ...

Grail said in a statement sent to Fierce Medtech that “the issue was in no way related to or caused by an incorrect Galleri laboratory test result.” Instead, per the company, its go-to telemedicine ...

Collaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of Care MENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- GRAIL, Inc.

Add Yahoo as a preferred source to see more of our stories on Google. Pancreatic cancer is the third leading cause of cancer-related deaths, trailing behind lung cancer and colorectal cancer, a trend ...

CHICAGO (Reuters) - U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial partnerships with health ...